🎉 M&A multiples are live!
Check it out!

Rhythm Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Rhythm Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Rhythm Pharmaceuticals Overview

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.


Founded

2008

HQ

United States of America
Employees

283

Website

rhythmtx.com

Financials

LTM Revenue $145M

LTM EBITDA -$239M

EV

$3.6B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Rhythm Pharmaceuticals Financials

Rhythm Pharmaceuticals has a last 12-month revenue of $145M and a last 12-month EBITDA of -$239M.

In the most recent fiscal year, Rhythm Pharmaceuticals achieved revenue of $130M and an EBITDA of -$238M.

Rhythm Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Rhythm Pharmaceuticals valuation multiples based on analyst estimates

Rhythm Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $77.4M $130M XXX XXX XXX
Gross Profit $21.5M $68.1M XXX XXX XXX
Gross Margin 28% 52% XXX XXX XXX
EBITDA -$168M -$238M XXX XXX XXX
EBITDA Margin -218% -183% XXX XXX XXX
Net Profit -$181M -$185M XXX XXX XXX
Net Margin -234% -142% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Rhythm Pharmaceuticals Stock Performance

As of April 15, 2025, Rhythm Pharmaceuticals's stock price is $60.

Rhythm Pharmaceuticals has current market cap of $3.8B, and EV of $3.6B.

See Rhythm Pharmaceuticals trading valuation data

Rhythm Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.6B $3.8B XXX XXX XXX XXX $-3.84

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Rhythm Pharmaceuticals Valuation Multiples

As of April 15, 2025, Rhythm Pharmaceuticals has market cap of $3.8B and EV of $3.6B.

Rhythm Pharmaceuticals's trades at 24.9x LTM EV/Revenue multiple, and -15.2x LTM EBITDA.

Analysts estimate Rhythm Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Rhythm Pharmaceuticals and 10K+ public comps

Rhythm Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.6B XXX XXX XXX
EV/Revenue 27.9x XXX XXX XXX
EV/EBITDA -15.2x XXX XXX XXX
P/E -14.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -31.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Rhythm Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Rhythm Pharmaceuticals Valuation Multiples

Rhythm Pharmaceuticals's NTM/LTM revenue growth is 50%

Rhythm Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Rhythm Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Rhythm Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Rhythm Pharmaceuticals and other 10K+ public comps

Rhythm Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 68% XXX XXX XXX XXX
EBITDA Margin -183% XXX XXX XXX XXX
EBITDA Growth 41% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -133% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 183% XXX XXX XXX XXX
Opex to Revenue 294% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Rhythm Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Rhythm Pharmaceuticals M&A and Investment Activity

Rhythm Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Rhythm Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Rhythm Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Rhythm Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Rhythm Pharmaceuticals

When was Rhythm Pharmaceuticals founded? Rhythm Pharmaceuticals was founded in 2008.
Where is Rhythm Pharmaceuticals headquartered? Rhythm Pharmaceuticals is headquartered in United States of America.
How many employees does Rhythm Pharmaceuticals have? As of today, Rhythm Pharmaceuticals has 283 employees.
Who is the CEO of Rhythm Pharmaceuticals? Rhythm Pharmaceuticals's CEO is Dr. David P. Meeker,M.D..
Is Rhythm Pharmaceuticals publicy listed? Yes, Rhythm Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Rhythm Pharmaceuticals? Rhythm Pharmaceuticals trades under RYTM ticker.
When did Rhythm Pharmaceuticals go public? Rhythm Pharmaceuticals went public in 2017.
Who are competitors of Rhythm Pharmaceuticals? Similar companies to Rhythm Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Rhythm Pharmaceuticals? Rhythm Pharmaceuticals's current market cap is $3.8B
What is the current revenue of Rhythm Pharmaceuticals? Rhythm Pharmaceuticals's last 12-month revenue is $145M.
What is the current EBITDA of Rhythm Pharmaceuticals? Rhythm Pharmaceuticals's last 12-month EBITDA is -$239M.
What is the current EV/Revenue multiple of Rhythm Pharmaceuticals? Current revenue multiple of Rhythm Pharmaceuticals is 24.9x.
What is the current EV/EBITDA multiple of Rhythm Pharmaceuticals? Current EBITDA multiple of Rhythm Pharmaceuticals is -15.2x.
What is the current revenue growth of Rhythm Pharmaceuticals? Rhythm Pharmaceuticals revenue growth between 2023 and 2024 was 68%.
Is Rhythm Pharmaceuticals profitable? Yes, Rhythm Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.